Philadelphia chromosome-like acute lymphoblastic leukaemia (Ph-like or BCR::ABL1-like ALL): lines of therapy
4 standard-of-care settings across 2 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.
Screening, prevention and diagnosis
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Diagnosis | Screen every B-ALL without BCR::ABL1 for the Ph-like signature and identify the kinase lesion; treat as high risk with MRD monitoring. | NCI PDQ: Childhood Acute Lymphoblastic Leukemia Treatment (health professional version) | 81 |
Other settings
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | ABL-class fusions | Dasatinib or imatinib added to high-risk chemotherapy from induction, as for Ph-positive ALL. | NCI PDQ: Childhood Acute Lymphoblastic Leukemia Treatment (health professional version) | 78 | |
| All comers | CRLF2, JAK2 or EPOR lesions | High-risk chemotherapy; ruxolitinib added in trials (AALL1521). | NCI PDQ: Childhood Acute Lymphoblastic Leukemia Treatment (health professional version) | 87 | |
| All comers | Persistent residual disease | Blinatumomab or CD19 CAR T-cells to clear residual disease, then allogeneic transplant. | NCI PDQ: Childhood Acute Lymphoblastic Leukemia Treatment (health professional version) | 92 |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.